Federal:
* 2R01CA148706-11: Targeting the colchicine binding site in tubulin for cancer therapy. July 2021-Jun
2026. Wei Li, PI.
* W81XWH-21-1-0055. Androgen Receptor-Targeted Treatment for Therapeutically Challenging Breast
Cancer. Department of Defense (DOD). Jan 2021-Dec 2023. Ramesh Narayanan, PI.
* R01CA229164-02S2. Racial Disparity in the Expression of Androgen Receptor Splice Variants
(ARSVs) in Prostate Cancer. National Cancer Institute (NCI). Oct 2020-Sept 2023. Ramesh Narayanan,
PI.
* 3R01CA229164-02S1. Novel degraders of androgen receptor (AR) and AR splice variants (ARSVs).
National Cancer Institute (NCI). Jul 2020-Jan 2024. Ramesh Narayanan, PI.
* 1R01CA253329. Role of microbial-modulated bile acid receptor signaling in breast cancer. National
Cancer Institute (NCI). Aug 2020-Jul 2025. Liza Makowski, PI.
* 1R01CA229164-01A1. Novel degraders of androgen receptor (AR) and AR splice variants (ARSVs).
National Cancer Institute (NCI). Feb 2019-Jan 2024. Ramesh Narayanan, PI.
Industry:
* Discovery and development of novel selective androgen receptor degraders (SARDs). GTx.,
Inc/Oncternal Inc. March 2015 – May 2021. Ramesh Narayanan, PI.